RenalGuard Solutions
Milford
About RenalGuard Solutions
Our newest product, RenalGuard®, has been developed to help prevent the onset of contrast-induced nephropathy (CIN) in at-risk patients undergoing certain imaging procedures. It is already approved for sale in the EU for general fluid balancing. Two investigator-sponsored European studies have demonstrated RenalGuard's effectiveness at preventing CIN. RenalGuard is being studied in a pivotal trial in the U.S., as required for approval by the FDA.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $21.5M
- Funding stage: Early Stage Venture
- Last round: Series B (Sep 2018)
- Website: renalguard.com
- Phone: (508)541-8800
Industries & Categories
Health Care, Manufacturing, Medical, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/renalguard-solutions-47574 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.